Are we done with dose-intense temozolomide in recurrent glioblastoma?

Neuro-Oncology

Volumn 16, Issue 9, 2014, Pages 1161-1163

  Van Den Bent, Martin J ^a,b   Taal, Walter ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ALKYLATING AGENT; DACARBAZINE;

ARTICLE; CANCER GROWTH; CHEMORADIOTHERAPY; DOSE DENSIFICATION; GLIOBLASTOMA; HUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RECURRENT GLIOBLASTOMA; TREATMENT DURATION; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; FEMALE; GLIOMA; MALE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; FEMALE; GLIOMA; HUMANS; MALE;

EID: 84906991854     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou157     Document Type: Article

References (24)

1. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, et al. Phase II Trial of 7days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014;16(9):1255-1262.
2. Tabatabai GWW, Steinbach JP, ick A, chnell O, Hau P, Herrlinger U, et al. MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial. J Clin Oncol 2014;32:5s, abstraact # 2015.
3. Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY. Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-935.
4. Wick W, Steinbach JP, Küker WM, Dichgans J, Bamberg M, Weller M. One week on/one week off: a novel active regimen of temozolomide for recurrent glioblastoma. Neurology 2004;62:2113-2115. (Pubitemid 38738235)
5. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, et al. Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 2006 Nov 6;95(9):1155-1160. (Pubitemid 44658477)
6. Brock CS, Newlands ES, Wedge SR. Phase I trial of Temozolomide using an extende continuous oral schedule. Cancer Res 1998;58:4363-4367. (Pubitemid 28450038)
7. Stupp R, Dietrich P-Y, Osterman-Kraljevic S, Pica A, Maillard I, Maeder P, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002;20:1375-1382. (Pubitemid 34177445)
8. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-996. (Pubitemid 40349501)
9. Mitchell RB, Moschel RC, Dolan ME. Effect of 06-benzylguanine on the sensitivity of human tumor xeongrafts to 1,3-bis (2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res 1992;52:1171-1175.
10. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000;18:3522-3528.
11. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350-1354.
12. Hegi ME, Diserens A-C, Gorlia T, Hamou M-F, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003. (Pubitemid 40349502)
13. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 2003;88:1004-1011. (Pubitemid 36560766)
14. Wick A, Felsberg J, Steinbach JP, Herrlinger U, Platten M, Blaschke B, et al. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. J Clin Oncol 2007 Aug 1;25(22):3357-3361. (Pubitemid 47325623)
15. Carson KA, Grossman SA, Fisher JD, Shaw EG. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol 2007 Jun 20;25(18):2601-2606. (Pubitemid 47041234)
16. Gorlia T, Stupp R, Brandes AA, Rampling RR, Fumoleau P, Dittrich C, et al. New prognostic factors and calculators for outcome prediction in patients with recurrent glioblastoma: a pooled analysis of EORTC Brain Tumour Group phase I and II clinical trials. Eur J Cancer 2012 May;48(8):1176-1184.
17. Galldiks N, Berhorn T, Blau T, Dunkl V, Fink GR, Schroeter M. "One week on-one week off": efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single center. J Neurooncol 2013 Apr;112(2):209-215.
18. Taal W, Segers-van Rijn JM, Kros JM, van H I, van der Rijt CC, Bromberg JE, et al. Dose-dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study. J Neurooncol 2012 May;108(1):195-200.
19. Yung WKA, Albright RE, Olson J, Frederick R, Fink D, Prados MD, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-593. (Pubitemid 30636298)
20. Perry JR, Belanger K, Mason WP, Fulton D, Kavan P, Easaw J, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol 2010 Apr 20;28(12):2051-2057.
21. Chamberlain MC, Glantz MJ, Chalmers L, Van HA, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 2007 Mar;82(1):81-83.
22. Taal W, Brandsma D, de Bruin HG, Bromberg JE, Swaak-Kragten AT, Sillevis Smitt PA, et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008 May 16;113:405-410.
23. Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013 Nov 10;31(32):4085-4091.
24. Brada M, Stenning S, Gabe R, Thompson LC, Levy D, Rampling R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol 2010 Oct 20;28(30):4601-4608.